Lemakalim
Alternative Names: BRL 38227; Levanex; Levcromakalim; Levro-cromakalimLatest Information Update: 16 Aug 2023
At a glance
- Originator GlaxoSmithKline
- Developer GlaxoSmithKline; Meiji Seika Kaisha
- Class Antiasthmatics; Antihypertensives; Benzopyrans; Bronchodilators; Small molecules
- Mechanism of Action KATP channel stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Arrhythmias; Asthma; Hypertension; Ischaemic heart disorders
Most Recent Events
- 15 Oct 2002 No development reported - Preregistration for Hypertension in Japan (PO)
- 23 Jan 2001 SmithKline Beecham has merged with Glaxo Wellcome to form GlaxoSmithKline
- 16 Dec 1999 Profile reviewed, but no significant modifications made